Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fondaparinux vs variable dose warfarin All causes of death · patients requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin Total VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.2 [0.01, 4.12] | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin Symptomatic VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin Total DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.2 [0.01, 4.12] | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin Proximal DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin Total PE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin Major bleeding · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 3 [0.32, 28.43] | 1 study · 236 participants | Very low |
Fondaparinux vs 1 mg warfarin All causes of death · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 236 participants | Very low |
Fondaparinux vs edoxaban Total VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Fondaparinux vs placebo Total DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.25 [0.15, 0.4] | 8 studies · 5715 participants | Moderate |
Fondaparinux vs edoxaban Symptomatic VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Fondaparinux vs edoxaban Total DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Fondaparinux vs edoxaban Proximal DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Ungraded |
Fondaparinux vs edoxaban Total PE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Fondaparinux vs edoxaban Major bleeding · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Fondaparinux vs edoxaban All causes of death · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Fondaparinux vs mechanical thromboprophylaxis Total VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.61 [0.22, 1.67] | 1 study · 99 participants | Low |
Fondaparinux vs mechanical thromboprophylaxis Symptomatic VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 120 participants | Low |
Fondaparinux vs mechanical thromboprophylaxis Total DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.63 [0.23, 1.72] | 1 study · 100 participants | Low |
Fondaparinux vs mechanical thromboprophylaxis Proximal DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 105 participants | Low |
Fondaparinux vs placebo Proximal DVT · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.12 [0.04, 0.39] | 7 studies · 2746 participants | Moderate |
Fondaparinux vs mechanical thromboprophylaxis Total PE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 120 participants | Low |
Fondaparinux vs mechanical thromboprophylaxis Major bleeding · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 120 participants | Low |
Fondaparinux vs mechanical thromboprophylaxis All causes of death · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 120 participants | Low |
Fondaparinux vs placebo Total PE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.16 [0.04, 0.62] | 8 studies · 6412 participants | High |
Fondaparinux vs placebo Major bleeding · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 2.56 [1.48, 4.44] | 8 studies · 6659 participants | Moderate |
Fondaparinux vs placebo All causes of death · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.76 [0.48, 1.22] | 8 studies · 6674 participants | Moderate |
Fondaparinux vs LMWH Total VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 0.55 [0.42, 0.73] | 11 studies · 9339 participants | Moderate |
Fondaparinux vs LMWH Symptomatic VTE · people requiring prevention of venous thromboembolism Pentasaccharides for the prevention of venous thromboembolism (2016) · Cochrane | RR 1.03 [0.65, 1.63] | 9 studies · 12240 participants | Moderate |
Padma 28 vs placebo Pain free walking distance (PFWD) · people with symptomatic intermittent claudication Padma 28 for intermittent claudication (2016) · Cochrane | no estimate extracted | 2 studies · 79 participants | Ungraded |
Padma 28 vs placebo Change in maximum walking distance (MWD) · people with symptomatic intermittent claudication Padma 28 for intermittent claudication (2016) · Cochrane | no estimate extracted | 1 study · 100 participants | Low |
Padma 28 vs placebo Final value MWD · people with symptomatic intermittent claudication Padma 28 for intermittent claudication (2016) · Cochrane | no estimate extracted | 2 studies · 193 participants | Very low |
Padma 28 vs placebo Adverse effects · people with symptomatic intermittent claudication Padma 28 for intermittent claudication (2016) · Cochrane | OR 1.09 [0.42, 2.83] | 4 studies · 231 participants | Very low |
Padma 28 vs placebo Final value ankle brachial index (ABI) · people with symptomatic intermittent claudication Padma 28 for intermittent claudication (2016) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Padma 28 vs placebo Change in ABI · people with symptomatic intermittent claudication Padma 28 for intermittent claudication (2016) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
10 mg warfarin nomogram vs 5 mg warfarin nomogram Therapeutic INR INR TEST · patients with venous thromboembolism. Warfarin initiation nomograms for venous thromboembolism (2016) · Cochrane | RR 1.27 [1.05, 1.54] | 3 studies · 383 participants | Moderate |
10 mg warfarin nomogram vs 5 mg warfarin nomogram Recurrent venous thromboembolism sonography or lung scan or chest computed tomography · patients with venous thromboembolism. Warfarin initiation nomograms for venous thromboembolism (2016) · Cochrane | RR 1.48 [0.39, 5.56] | 3 studies · 362 participants | Low |
10 mg warfarin nomogram vs 5 mg warfarin nomogram Major bleeding fall in hemoglobin of > 20 g/L or transfusion of 2 or more units of red cells · patients with venous thromboembolism. Warfarin initiation nomograms for venous thromboembolism (2016) · Cochrane | RR 0.97 [0.27, 3.51] | 4 studies · 494 participants | Moderate |
10 mg warfarin nomogram vs 5 mg warfarin nomogram Minor bleeding it is not major bleeding · patients with venous thromboembolism. Warfarin initiation nomograms for venous thromboembolism (2016) · Cochrane | RR 0.52 [0.15, 1.83] | 2 studies · 243 participants | Very low |
10 mg warfarin nomogram vs 5 mg warfarin nomogram Length of hospital stay record of hospitalization · patients with venous thromboembolism. Warfarin initiation nomograms for venous thromboembolism (2016) · Cochrane | no estimate extracted | 1 study · 111 participants | Low |
Venous cutdown vs Seldinger technique Success of primary implantation · patients requiring an elective TIVAP insertion for treatment of benign or malignant disease Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports (2016) · Cochrane | OR 0.4 [0.25, 0.65] | 7 studies · 1006 participants | Moderate |
Venous cutdown vs Seldinger technique Overall perioperative and postoperative complications · patients requiring an elective TIVAP insertion for treatment of benign or malignant disease Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports (2016) · Cochrane | OR 1.16 [0.76, 1.75] | 7 studies · 1006 participants | Moderate |
Venous cutdown vs Seldinger technique Pneumothorax · patients requiring an elective TIVAP insertion for treatment of benign or malignant disease Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports (2016) · Cochrane | OR 1.97 [0.53, 7.34] | 7 studies · 1006 participants | Moderate |
Venous cutdown vs Seldinger technique Infections · patients requiring an elective TIVAP insertion for treatment of benign or malignant disease Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports (2016) · Cochrane | OR 0.63 [0.25, 1.56] | 6 studies · 906 participants | Moderate |
Venous cutdown vs Seldinger technique Catheter/port‐related complications · patients requiring an elective TIVAP insertion for treatment of benign or malignant disease Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports (2016) · Cochrane | OR 1 [0.61, 1.64] | 7 studies · 1006 participants | Moderate |
Subintimal angioplasty with stenting vs remote endarterectomy Clinical improvement: Rutherford classification improvement Rutherford classification · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.79 [0.61, 1.03] | 1 study · 95 participants | Low |
OUTBACK re‐entry catheter vs manual re‐entry Technical success rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 1 [0.93, 1.08] | 1 study · 52 participants | Low |
OUTBACK re‐entry catheter vs manual re‐entry months' patency rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 1.04 [0.94, 1.15] | 1 study · 52 participants | Low |
OUTBACK re‐entry catheter vs manual re‐entry months' patency rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 1.09 [0.9, 1.33] | 1 study · 52 participants | Low |
OUTBACK re‐entry catheter vs manual re‐entry months' primary patency rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Ungraded |